Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 493

Results For "MED"

5604 News Found

Alcon announces launch of AcrySof IQ Vivity in India,
Medical Device | October 19, 2021

Alcon announces launch of AcrySof IQ Vivity in India,

It is the first presbyopia-correcting lens implant for cataract surgery


Dr Reddy’s Labs announces U.S. FDA approval for Lenalidomide capsules
Drug Approval | October 19, 2021

Dr Reddy’s Labs announces U.S. FDA approval for Lenalidomide capsules

The company is eligible for 180 days of generic drug exclusivity for Lenalidomide capsules, 2.5 mg and 20 mg


MSN Labs launches drug for diabetes management
Drug Approval | October 19, 2021

MSN Labs launches drug for diabetes management

The company claims that its Empagliflozin tablets are the most affordable in India


Vertex’s stem cell therapy for Type 1 diabetes reduced daily insulin requirement by 91 %
Biotech | October 19, 2021

Vertex’s stem cell therapy for Type 1 diabetes reduced daily insulin requirement by 91 %

The first patient dosed with VX-880 demonstrated restoration of insulin production and achieved C-peptide of 560 pmol/L in response to Mixed Meal Tolerance Test (MMTT) at Day 90 visit


AstraZeneca ties up with Rajiv Gandhi Cancer Institute to treat patients with Chronic Lymphocytic Leukemia
Healthcare | October 19, 2021

AstraZeneca ties up with Rajiv Gandhi Cancer Institute to treat patients with Chronic Lymphocytic Leukemia

Rajiv Gandhi Cancer Institute (RGCI), Delhi one of Asia’s premier institutes becomes the first strategic partner to adopt and implement Project Chariot in patients across North India & Delhi NCR region


WHO to take call on Covaxin's EUL on October 26th
News | October 18, 2021

WHO to take call on Covaxin's EUL on October 26th

The WHO chief scientist Soumya Swaminathan tweeted on Oct. 17


U.S. FDA approves Roche’s Tecentriq as adjuvant treatment for small cell lung cancer
Drug Approval | October 18, 2021

U.S. FDA approves Roche’s Tecentriq as adjuvant treatment for small cell lung cancer

Tecentriq is the first and only cancer immunotherapy approved for NSCLC in the adjuvant setting


Imfinzi plus tremelimumab significantly improved overall survival in liver cancer
Biotech | October 18, 2021

Imfinzi plus tremelimumab significantly improved overall survival in liver cancer

The trial met the primary endpoint of overall survival with a single priming dose of tremelimumab plus Imfinzi every four weeks vs. sorafenib


U.S. FDA advisory committee recommends J&J booster dose
Biotech | October 18, 2021

U.S. FDA advisory committee recommends J&J booster dose

U.S. FDA to decide whether to authorize a booster dose in the coming days


Ipsen enters exclusive worldwide tie-up with Accent for its pre-clinical R&D oncology pipeline
Biotech | October 18, 2021

Ipsen enters exclusive worldwide tie-up with Accent for its pre-clinical R&D oncology pipeline

Ipsen obtains an exclusive license to develop, manufacture and commercialize a pre-clinical stage METTL3-inhibitor programme